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ABSTRACT
Objectives: To evaluate an electronic patient referral
system from one UK hospital Trust to community
pharmacies across the North East of England.
Setting: Two hospital sites in Newcastle-upon-Tyne
and 207 community pharmacies.
Participants: Inpatients who were considered to
benefit from on-going support and continuity of care
after leaving hospital.
Intervention: Electronic transmission of an
information related to patient’s medicines to their
nominated community pharmacy. Community
pharmacists to provide a follow-up consultation tailored
to the individual patient needs.
Primary and secondary outcomes: Number of
referrals made to and received by different types of
pharmacies; reasons for referrals; accepted/completed
and rejected referred rates; reasons for rejections by
community pharmacists; time to action referrals;
details of the follow-up consultations; readmission
rates at 30, 60 and 90 days post referral and number
of hospital bed days.
Results: 2029 inpatients were referred over a 13-
month period (1 July 2014–31 July 2015). Only
31% (n=619) of these patients participated in a
follow-up consultation; 47% (n=955) of referrals were
rejected by community pharmacies with the most
common reason being ‘patient was uncontactable’
(35%, n=138). Most referrals were accepted/
completed within 7 days of receipt and most
rejections were made >2 weeks after referral receipt.
Most referred patients were over 60 years of age and
referred for a Medicines Use Review (MUR) or
enrolment for the New Medicines Service (NMS).
Those patients who received a community pharmacist
follow-up consultation had statistically significant
lower rates of readmissions and shorter hospital
stays than those patients without a follow-up
consultation.
Conclusions: Hospital pharmacy staff were able to
use an information technology (IT) platform to improve
the coordination of care for patients transitioning back
home from hospital. Community pharmacists were
able to contact the majority of patients and results
indicate that patients receiving a follow-up consultation
may have lower rates of readmission and shorter
hospital stays.
INTRODUCTION
The continuity of patient care when transi-
tioning from one healthcare setting to
another is a national priority.1 A range of
interventions have been designed, trialled
and tested to improve the quality and safety
of this transfer process.2–6 Successful inter-
ventions have incorporated activities such as
medication reconciliation; quick, clear and
structured discharge summaries; discharge
planning; follow-up between hospital and
Strengths and limitations of the study
▪ This study provides a detailed description of how
an electronic referral system between hospital
and community pharmacies across the North
East of England was implemented.
▪ This study demonstrates that inpatients can be
effectively referred to their nominated community
pharmacist and receive a follow-up consultation
tailored to their needs after discharge from the
hospital.
▪ The study demonstrates that routine data collec-
tion during this evaluative period requires critical
analysis and additional qualitative work to under-
stand fully the operational and implementation
aspects of the service, for example, complex
reasons for the recorded rates of non-completion
of referrals.
▪ There are no routinely recorded data at the com-
munity pharmacist follow-up consultation to
allow specific economic, clinical or humanistic
outcomes to be determined. However, service
continual improvements are being made towards
achieving this.
▪ A well-structured clinical trial of this intervention
is required to investigate the impact on patients
as they transition between healthcare settings.
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community providers; electronic discharge notifications;
and web-based access to discharge information for
general practitioners (GPs).7 In the design of such inter-
ventions, community pharmacists have been recognised
as accessible and valuable contact points for patients in
primary care to provide additional advice and counsel-
ling, particularly on medication-related issues and the
management of chronic conditions.8–11 A recent system-
atic review highlighted how community pharmacists
could help identify and rectify medication errors, thus
providing a significant impact on improving outcomes.8
These community pharmacy interventions included
activities to improve the quality of information; coordin-
ation of care and communication between care settings.8
Other reported outcomes that could be realised include:
improved patient understanding of their medication and
condition,5 12 improved communication of accurate
medication-related information between care settings5
and the potential to reduce morbidity and mortality
associated with targeted conditions.11 13
In 2012, the Royal Pharmaceutical Society (RPS)
issued professional guidance in its publication ‘Keeping
patients safe when they transfer between care providers—getting
the medicines right’ on the core principles that underpin
the safe transfer of information related to medicines for
a patient transferring between care providers in any
setting.14 Hospital and community sites across the UK
have adopted this guidance by designing services and
initiatives to specifically improve patient transitions. In a
subsequent report,15 30 early adopter sites provided
information to the RPS on their service designs; the bar-
riers they faced; their results and how the initiatives will
sustain change and facilitate good practice locally going
forward. Of these sites, half incorporated a specific role
for community pharmacists within their transfer of care
programmes,15 and three were used as exemplar case
studies by the RPS in their most recent toolkit16 to
support hospital referral services to community phar-
macy. This document was issued to aid commissioners
and pharmacy leaders to design and implement an
effective referral system.16 However, despite the valuable
structure and support this document provided at an
aerial level, no evaluation has been conducted of a trans-
fer of care initiative incorporating active involvement of
community pharmacists since the RPS professional guid-
ance was issued.14 We evaluated the transfer of care ini-
tiative in the North East of England and North Cumbria,
and present aspects of its achievement from two specific
hospital sites where the initiative has been delivered for
the longest period of time and generated the most
service activity data.
METHODS
Description of the service intervention
The transfer of care initiative, the first of its kind in the
UK, was launched in July 2014. It was a collaborative
project between Newcastle-upon-Tyne National Health
Services (NHS) Foundation Trust, North of Tyne Local
Pharmacy Committee (LPC) and Pinnacle Health
Partnership LLP (provider of PharmOutcomes).
PharmOutcomes is a web-based platform routinely used by
community pharmacies in the North East and North
Cumbria to record data on service provision. The three
parties involved in the collaboration created new hos-
pital and community pharmacy referral templates within
PharmOutcomes to facilitate a secure method of electronic
transfer of information related to medicines between
hospital and community pharmacies.16 Hospital phar-
macy staff were shown how to use PharmOutcomes by
senior pharmacy staff, and two launch events were orga-
nised for hospital and community pharmacy staff to
inform and answer any questions about the electronic
patient referral process. Community pharmacy staff were
also provided with further information in paper-based
and electronic forms, and screenshots to help visualise
the content of information that would be received by
the community pharmacists. Newcastle-upon-Tyne hospi-
tals were the first hospitals to make electronic referrals
to community pharmacies, and it is their service that has
been analysed; however, following creation of an
Academic Health Science Network (AHSN) transfer of
care initiative (October 2014), eight other hospitals in
the North East and North Cumbria are now also making
referrals using PharmOutcomes. The service intervention
has been described in further detail using the Template
for Intervention Description and Replication (TIDier)
checklist and guide (see online supplementary file 1).17
Since its conception, the service has been developed
and the changes have been itemised (see online
supplementary file 2). These will be referred to as find-
ings are discussed.
Referrals sent from the hospital system
Hospital pharmacy staff, which include pharmacy techni-
cians and clinical pharmacists (approximately n=30
across the two hospital sites) identified patients who, in
their clinical judgement, would benefit from a follow-up
consultation with a community pharmacist. These
included patients who were on four or more medicines
or had a number of medicines changed during their
hospital stay. These patients were approached, informed
about the service, and asked if they would like to partici-
pate and nominate a community pharmacy of their
choice. At the time of the patient’s discharge, a member
of hospital pharmacy staff (pharmacy technicians and
clinical pharmacists) would (a) log into PharmOutcomes,
(b) populate various patient demographic fields includ-
ing name; date of birth; postcode; ethnicity; NHS
number; GP details, (c) select a community pharmacy
(nominated by the patient) from a drop-down list and
(d) recommend what additional pharmaceutical service,
advice or general care might be useful for the patient at
the follow-up consultation (‘Reason for referral’ field).
Finally, the contact details of the member of staff
making the referral were also recorded.
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Referrals received by the community pharmacy system
Community pharmacists could participate on a voluntary
basis, as no contractual or service reimbursement
arrangements were made. Community pharmacists had
the choice of either ‘accepting’ or ‘rejecting’ the referral
sent from the hospital. From December 2014, if a refer-
ral was rejected, the community pharmacist was
prompted to provide a reason from the drop-down list,
which included ‘housebound patient’, ‘uncontactable
patient’ and ‘other’. If ‘other’ was selected, then further
details were required in the free text box provided. The
drop-down list was changed in June 2015 to increase the
options available and to force the selection of a reason
for rejection, removing ‘housebound patient’ as the
default. Alternatively, the community pharmacist could
choose to ‘accept’ the referral and, thus, contacted the
patient to arrange a follow-up consultation. Further
details on what medication-related questions were asked
to the patient during the consultation were collected for
example, was the patient’s understanding of how to take
medications checked?; has the patient experienced an
adverse drug reaction (ADR)? Any pharmaceutical
service(s) that were provided to the patient needed to
be recorded by the pharmacist for example, Medicines
Use Review (MUR) or stop smoking service, as well as
any support service(s) for example, medicines reconcili-
ation or review of a compliance aid. Once the consult-
ation had been completed, the pharmacist was required
to enter further details in PharmOutcomes under the
section ‘Complete the referral’. These details included
name and address of the community pharmacy; name
and professional registration number of the community
pharmacist; the reported long-term condition(s) of the
patient (cardiovascular disease; respiratory; diabetes and
other). If a community pharmacist had not acknowl-
edged the referral in PharmOutcomes nor registered any
action taken, then the status of that referral remained
recorded as ‘Referred (no action)’ on the system. Data
on community pharmacy activity were captured through
PharmOutcomes.
Data collection
Service activity data
We evaluated this service from 1 July 2014 to 31 July
2015. All patient identifiable information was removed;
however, patient age, ethnicity and postcode were
included. The reasons for referrals by hospital staff, the
details of the community pharmacies to which referrals
were sent, and the subsequent acceptance/rejection and
completion rate of these referrals were extracted.
Community pharmacies were categorised by type as
follows: national large chain multiple, small regional
chain multiple, supermarket pharmacy and independent
pharmacy. The referral history was tracked to investigate
how many referrals were actioned, that is, ‘accepted’,
‘completed’ or ‘rejected’ within 7; 7–14; and >14 days.
Where referrals were rejected, the reasons provided
were collated and analysed. Details on the long-term
conditions of the patients referred, their specified medi-
cation regimen, the medicine-related questions asked by
the pharmacist at the follow-up consultation, any
general patient feedback as recorded by the pharmacist,
any reported ADRs and the advice given as a conse-
quence, and any additional pharmaceutical or support
services that was provided, were also collated and
analysed.
Hospital readmission rates and number of bed days
On 23 October 2015 the NHS numbers of all patients
who participated in the electronic referral service
between 1 July 2014 and 30 June 2015 were extracted by
the hospital team and checked to see if they had been
readmitted (all-cause admissions) post electronic referral
and, if so, what specific dates they had been subse-
quently admitted and discharged on. Patients participat-
ing in the service after 30 June 2015 would not have had
readmission data at 90 days post referral, hence the
shorter analysis period was chosen. The data were anon-
ymised and sent to an independent researcher (HN).
The patient population was categorised into two groups:
one received a community pharmacist follow-up consult-
ation (completed referrals) and one did not (either
accepted but not completed, referred (no action), and
rejected referrals). The number of readmissions at 30,
60 and 90 days post electronic referral was collated and
number of bed days was calculated from length of hos-
pital stays.
Data analysis
Quantitative data relating to the service activity was ana-
lysed using descriptive statistics and converted to percen-
tages where appropriate to represent proportions. Text
entered into free text boxes were collated, manually
coded and then analysed. Readmission was defined as a
stay of at least 12 hours. Association between the
outcome of referrals (accepted, remain referred, com-
pleted, rejected) and type of pharmacy (eg, supermar-
ket, independent, etc) were examined using a χ2 test. A
generalised estimating equation model was used to
examine the association between readmission rate and
whether patient received consultation or not from the
community pharmacies. As repeated readmissions per
patient at 30, 60 and 90 days are likely to be correlated,
this model accounted for intrapatient correlation
between the repeated data. Similarly, number of days
admitted were analysed using linear model with a struc-
tured covariance matrix to account for repeated
readmission data per patient.
Discussion within the project team, together with
hospital research ethics leads and on consultation of
the NHS Health Research Authority guidance18 identi-
fied the study components to be either audit or
service evaluation and therefore did not require
ethical approval.
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RESULTS
Service activity data
A total of 2029 hospital inpatients consented to partici-
pate in the transfer of care service during the evaluative
period and were referred to their nominated community
pharmacy. Of these, 97.9% (n=1986) referrals were gen-
erated by pharmacy technicians. The spread of these
referrals over the 13 months are shown in figure 1. This
equated to ∼156 referrals being made each month to
207 community pharmacies across the North of Tyne,
that is, ∼0.75 referrals per month per pharmacy. The
rate of referrals fluctuated throughout the year, but gen-
erally numbers increased with the highest occurring in
July 2015.
Community pharmacies were categorised according to
Bush et al: supermarket; multiple (≥200 outlets); large
chain (>20 outlets but <200); small chain (≤20 outlets
but >5); independent (≤5 outlets).19 Table 1 shows how
many referrals were received by each pharmacy type and
whether these referrals were accepted, rejected or com-
pleted. Overall, table 1 shows that outcomes of referrals
varied significantly among the various types of pharma-
cies (p<0.001). This pattern was consistent for each
outcome (accepted, remain referred, completed,
rejected). Completion of referrals was highest for multi-
ples and significantly higher than any other type of
pharmacy. Rejection was highest among small chain
pharmacies and was significantly higher than rejection
rates from all other types of pharmacy.
The decision to either accept or complete the referrals
was largely carried out within 7 days of the community
pharmacist receiving the referral (56.1% and 66.2%,
respectively) as shown in online supplementary file 3.
However, most rejections were made >7 days post dis-
charge (66.9%).
Of the total 2029 referrals, 45.3% (n=955) were
rejected by the community pharmacy. The 389 rejections
that occurred after December 2014 were accompanied
with a reason, which are listed in online supplementary
file 4. The most common reason for rejection was that
the patient was uncontactable (35.5%, n=138) or that
the patient was housebound (19.3%, n=75). However,
after a change made to the PharmOutcomes template in
June 2015 that removed ‘housebound’ as the default
reason for rejecting a referral (see online
supplementary file 2), the rate of rejection for this
reason dropped from 39% to 14%.
The age range of patients who agreed to receive a
referral and the reasons for these referrals, of which
there could be multiple reasons, were recorded by hos-
pital pharmacy staff (table 2).
Only 30.5% (n=619) of referrals made resulted in a
community pharmacist ‘accepting’ and recording the
‘completion’ of the follow-up consultation. Table 3
details the long-term condition or treatment of patients
receiving a follow-up by a community pharmacist, the
medication-related information they were provided with
during the consultation, any advice on ADRs and any
additional pharmaceutical or support service that was
also delivered.
The majority of patients that were followed up were
those with a cardiovascular or respiratory disease. Most
patients received information from the community
pharmacist on their medication (90.0%, n=557), doses
(87.8%, n=543), occurrence of side effects (84.2%,
n=521) and their conditions (73.8%, n=457). Most
patients (73.8%, n=457) did not report an ADR to the
community pharmacist during the consultation.
However, of those who did, 17.1% (n=106) were consid-
ered manageable and non-harmful to the patient, and
thus, the patients were advised to continue taking their
medication as prescribed. Most patients did not receive
any additional pharmaceutical or support service
(53.4%, n=331), but many received an MUR (46.6%,
n=288) and/or were enrolled on the New Medicines
Service (NMS) (38.9%, n=241). Of these patients who
Figure 1 The number of
referrals made over the evaluative
period.
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were provided with a follow-up consultation, 40.4%
(n=250) provided feedback via the pharmacist. Just over
half of these patients reported that the information was
a good reconfirmation of the information provided
within hospital and, at discharge (52.4%, n=131), 90
(36%) of the patients expressed their appreciation for
the contact with the community pharmacist and the use-
fulness of their advice and/or service provided through
this initiative; a small number (4.8%, n=12) refused or
were reluctant to receive any form of follow-up consult-
ation by the community pharmacist in the future. In the
remainder of cases (6.8%, n=17), pharmacists recorded
how the patient was either too ill to be spoken to or that
they consulted with their carer instead.
Hospital readmissions and number of bed days
There were a total of 1386 hospital patients who received
electronic referrals to community pharmacy during the
period 1 July 2014 and 30 June 2015; of these, 501
(36.1%) had a record of receiving a follow-up consult-
ation by a community pharmacist (‘completed’ referral)
(table 4). Of the remaining 885, 278 (20.0%) patients
are unlikely to have received a follow-up community
pharmacist consultation as the status of their referral on
the PharmOutcomes system remained either ‘referred (no
action)’, ‘accepted’ but not completed. A total of 607
(43.8%) were ‘rejected’ by the community pharmacist.
Table 4 displays the readmissions rates and number of
bed days of patients who either received or did not
receive a follow-up community pharmacist consultation.
The odds of readmission were found to be significantly
higher among those who did not receive a follow-up
consultation from the community pharmacy. This result
is consistent across the three readmission time points
(30, 60 and 90 days). Over the same time period, the
30 day readmission rate was 13.2%, which is higher than
that of the group of patients who received the commu-
nity pharmacist follow-up and lower than that of the
patients who did not receive the community pharmacist
follow-up. This correlation appears to indicate that hos-
pital pharmacy staff were targeting patients at greatest
risk of early readmission to hospital. Among readmitted
patients, the average duration of hospital stay at any time
point (30, 60 or 90 days) was at least 5 days less for those
who received consultation.
DISCUSSION
This transfer of care service addressed a recognised
patient need as they transition between care settings.
Our findings show how an electronic solution, in this
case PharmOutcomes, can be employed to facilitate the
transfer of information between hospital and community
pharmacy teams to improve the coordination of care as
patients transfer between care settings. We have provided
a detailed description of how this specific electronic
Table 1 The number of referrals received across the categories of community pharmaciesa–d and the subsequent outcomes
of those referrals
Type of pharmacy
Outcome
of referrals Independent n (%) Multiples n (%)
Supermarket
n (%)
small chain
n (%) Total n (%) P value
Accepted 39 (7.7)a,c* 70 (6.6)b,c* 26 (20.3)c,d* 33 (9.6) 168 (8.3) 0.009
Remain referred 108 (21.6)a,b*; a,d*both 168 (15.8)b,d* 18 (14.1)c,d* 4 (1.1) 298 (14.7) <0.001
Completed 128 (25.5)a,b*; a,c* 396 (37.5)b,c; b,d all* 20 (15.6) 75 (21.9) 619 (30.5) <0.001
Rejected 226 (45.1)a,d* 423 (40.0)b,c; b,d both* 64 (50.0)c,d* 231 (67.3) 944 (46.5) <0.001
Total 501 (24.7) 1057 (52.1) 128 (6.3) 343 (16.9) 2029 (100.0) <0.001
*Denotes statistically significant difference at p<0.05 between pharmacy types.
Table 2 The age of the patients and reasons for the
referrals made by hospital pharmacy staff to community
pharmacy during the evaluative period. (n=2029)
Characteristics of referrals Number (%)
Age of patient (years)
<10 47 (2.3)
11–19 14 (0.7)
20–29 24 (1.2)
30–39 65 (3.2)
40–49 183 (9.0)
50–59 270 (13.3)
60–69 497 (24.5)
≥70 930 (45.8)
Reason for referral
MUR 663 (32.7)
New medication(s) issued in hospital 365 (18.0)
Compliance aid issue 168 (8.3)
Changed dose(s) in hospital 148 (7.3)
Stopped medication(s) in hospital 142 (7.0)
Compliance issues 77 (3.8)
MUR/New Medicines Service (NMS) 73 (3.6)
Technique issue 57 (2.8)
Smoking cessation follow-up 43 (2.1)
NMS 30 (1.5)
Side effect issue 26 (1.3)
Need for monitoring 24 (1.2)
Check on well-being 16 (0.8)
Repeat dispensing query 10 (0.5)
Delivery service query 10 (0.5)
Special formulation of medication 4 (0.2)
No reason provided 601 (29.6)
MUR, medicines use review.
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referral process worked in practice, so as to help inform
future service designers and implementers. We also
provide information of the ongoing changes made
during the evaluation period which aimed to increase
rates of referrals, completion and reduce rejections.
Additional changes have and are being made in
response to continuing evaluation of the service delivery
and activity. We found that community pharmacy
engagement, through linking with local pharmacy
committees and regional managers of large multiples,
along with close working relationships with the develo-
pers of the eReferral platform, were key to designing,
adapting and delivering a successful process.
Over the 13-month evaluative period, 2029 patients
were referred to their nominated community pharmacy.
This is a modest number of referrals considering there
were no eligibility criteria to restrict activity. Ramsbottom
et al20 also report a very small proportion of eligible
inpatients (3.2% of over 10 000 potential patients) were
identified to receive referrals to community pharmacists
for domiciliary MURs. The main reasons put forward by
the authors for these low referral rates were that the
service was new and not embedded into practice, hos-
pital staff had other competing priorities and the
patients’ poor health were reported as barriers to
making referrals.20 Further qualitative data collection
from hospital pharmacy staff could explore the reasons
for low referral rates in our study and aid in the design
of solutions to increase activity. Qualitative data from
community pharmacists would also explore the low com-
pletion rate, and investigate the facilitators and barriers
to the embedding of this service into normal practice.
The Normalisation Process Model, as proposed by May21
would be an appropriate theoretical framework to evalu-
ate the process and context of implementation.
Unfortunately, we did not record the details of all
patients who were approached by hospital pharmacy
staff and offered an electronic referral. It would be inter-
esting to further investigate why patients decided to
refuse these referrals. A recent study found that 32% of
elderly patients eligible to receive a visit from a pharma-
cist post hospital discharge refused. The most common
reasons stated in this study were the lack of perceived
benefit of the interaction with a community pharmacist
and preference to see their GP.20 Yu et al22 also found
that once their patient population was made aware of
the availability and benefits of a post discharge pharma-
cist home medicines review, the majority of patients were
willing to participate.22
Most referrals were sent to multiple chain pharmacies
(52.1%, n=1057) as nominated by inpatients. Multiple
chain pharmacies made up 50.2% of the total number
of pharmacies in the area (104 out of 207). This cat-
egory of pharmacy also had the highest completion rate
of eReferrals, significantly higher than all other phar-
macy types (35.6%, n=376). The supermarket pharma-
cies received the least number of eReferrals (6.3%,
n=128) and also had the lowest completion rate (15.8%,
n=20), which was statistically lower than all other phar-
macy types. Further investigation is needed to explore
the motivators and barriers of pharmacists to accept/
refuse eReferrals and whether the type of pharmacy at
which the pharmacist was based influenced their deci-
sion. Work carried out by Jacobs et al23 24 may provide a
framework in evaluating if and how the culture in
various community pharmacy organisations impact their
performance in pharmaceutical services. Another
Table 3 The details of the referrals that were followed up
by community pharmacists and recorded as completed.
(n=619)
Completed referral details
Number of
patients (%)
Long-term condition/treatment of patient
Cardiovascular disease (CVD) 328 (53.0)
Respiratory 126 (20.4)
Diabetes 28 (4.6)
CVD and diabetes 22 (3.5)
Pain 11 (1.8)
Cancer 9 (1.4)
Anticoagulant 8 (1.3)
CVD and other 7 (1.1)
Diabetes and other 3 (0.5)
Hypertension 1 (0.2)
None specified 76 (12.3)
Information provided
More information on medication(s) 557 (90.0)
Dose check 543 (87.8)
More information on condition 457 (73.8)
Side effect check 521 (84.2)
Advice provided on reported ADR
Manageable and non-harmful—patient to
continue
106 (17.1)
Refer to GP 33 (5.4)
Patient stopped taking medication 18 (2.9)
Refer to hospital 5 (0.8)
Not applicable 457 (73.8)
Pharmaceutical/support service provided
MUR 288 (46.6)
NMS 241 (38.9)
Home delivery service 138 (22.3)
Compliance aid 79 (12.8)
Repeat dispensing 53 (8.5)
Medicines reconciliation 28 (4.5)
Smoking cessation 25 (4.0)
Discussion 23 (3.7)
Review of dosage form 17 (2.7)
Review of compliance aid 13 (2.1)
Influenza vaccination 12 (1.9)
Medication administration record 7 (1.1)
Large print labels 7 (1.1)
Easy open tops 6 (1.0)
Healthy living advice 6 (1.0)
Appliance use review 1 (0.2)
None 331 (53.4)
ADR, adverse drug reaction; GP, general practitioner; MUR,
medicines use review; NMS,New Medicines Service.
6 Nazar H, et al. BMJ Open 2016;6:e012532. doi:10.1136/bmjopen-2016-012532
Open Access
group.bmj.com on April 19, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
evaluation of a pharmaceutical service using
PharmOutcomes for routine data collection suggested that
low recorded completion rates on this information tech-
nology (IT) platform may have been due to the commu-
nity pharmacists not logging onto the system and
documenting their actions.25 In which case the referrals
that are listed as ‘remain referred’ or ‘accepted’ may
have actually been formally completed or rejected. Most
eReferrals were ‘accepted’ or ‘completed’ within 7 days
of receipt, whereas most rejections occurred after 7 days.
It is important to understand this time lag and whether
the delay was due to events not under the community
pharmacist’s control, for example, multiple attempts to
contact the patient. The most highly reported reasons
for rejections of referrals by the community pharmacists
was that the patient was uncontactable (35.1%, n=138).
Specific reasons for this needs to be explored to under-
stand if this is an issue with the service design and deliv-
ery, for example, patients may not answer unidentifiable
numbers; patients may provide erroneous contact details
instead of refusing a referral, etc. A considerably large
number of pharmacist rejections in our study were due
to the patients being housebound (19.3%, n=75);
however, it was observed that rates of patients registered
as ‘housebound’ dropped from 19% of rejections to
14%, after the change was made on the electronic tem-
plate. Where the referral had been sent to a pharmacy
which was not routinely used by the patient (12.4%,
n=48), again further understanding is required to check
if this is something that could be further improved in
the design of the service or patient deflection. It is pos-
sible that patients newly prescribed medicines who were
not taking medicines prior to admission to hospital (eg,
post myocardial infarction (MI)) and, therefore, not
known by the community pharmacy had their referral
rejected when their need for support was greatest.
Further detailed analysis is therefore warranted.
The majority of patients that consented for an elec-
tronic referral were elderly (60 years and over, 70.3%,
n=1427) and the most common reasons that a referral
was made by hospital staff were for medication–related
problems (MUR; initiation/cessation/changed medi-
cine or dose in hospital; compliance aid issue; medica-
tion compliance issue). The patients who ultimately
received a follow-up consultation from a community
pharmacist were those with reported cardiovascular
disease (53.0%, n=328) or a respiratory condition
(20.4%, n=126). This may reflect the areas in the hos-
pital being targeted by clinical pharmacy staff; however,
empirical research is required to investigate this. These
patient demographics may be useful to consider in
defining eligibility criteria for the referral of future
patients. Within the follow-up consultation pharmacists
had the opportunity to provide information on medica-
tion, dosing, medical condition, side effects/ADRs and
their subsequent management. Most of the patients
were not provided with an additional pharmaceutical
or support service (53.4%, n=331), but 46.6% (n=288)
of patients received an MUR and/or initiated the NMS
(38.9%, n=241).
Routine data collection does not include a measure
that meets any economic, clinical or humanistic out-
comes model;26 this means that the impact and value of
the intervention cannot be understood. Despite the tai-
loring of the community pharmacist follow-up consult-
ation to the patient’s expressed need, no subsequent
outcome data associated with the tailored pharmaceut-
ical care and/or service are routinely recorded to dem-
onstrate the effect. Where MURs were performed or
NMS initiated, there is no inclusion of the actions and
recommendations of the community pharmacist within
routine data collection on PharmOutcomes. The informa-
tion for these two specific services has their own separate
documentation and recording process. Inclusion of this
information with the eReferral service data may provide
further detail on the impact of the community pharma-
cist intervention on patient outcomes, for example,
medication or condition-related issues and advice, refer-
rals onto GPs for monitoring or consultation. Future eva-
luations should aim to identify a specific parameter that
can be used directly or as a proxy to measure economic,
humanistic or clinical outcomes.
Table 4 The readmissions and number of bed days of patients who received a follow-up community pharmacist consultation
and of patients who did not
Patient cohort
Number of readmissions post electronic
referral at
Number of bed days for readmitted
patients at
0–30 days
n (%)
31–60 days
n (%)
61–90 days
n (%)
30 days
mean±SD
60 days
mean±SD
90 days
mean±SD
Received a CP
consultation (n=501)
29 (5.8) 17 (3.4) 18 (3.6) 7.2±1.0 7.2±6.4 7.3±6.7
Did not receive CP
consultation (n=885)
142 (16.0) 84 (9.5) 83 (9.4) 13.1±17.4 13.7±19.2 12.5±16.6
OR and 95% CIs
(N=1386)
3.1 (2.1 to 4.7) 3.0 (1.8 to 5.1) 2.8 (1.6 to 4.7)
Mean differences and
95% CIs (N=373)
−5.8
(−12.7 to 1.0)
−6.5
(−15.4 to 2.4)
−5.2
(−13.9 to 3.5)
CP, community pharmacist.
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Of the relatively small proportion of patients who pro-
vided ad hoc feedback via the pharmacist about the
service, just over half felt that the information received
reconfirmed what they had been previously told in hos-
pital; some patients appreciated this and found it useful.
Our study found that those patients who received a
follow-up community pharmacist consultation as a result
of a hospital eReferral demonstrated statistically lower
readmissions and shorter hospital stays as a result of any
readmission. However, further critical analysis of this
positive association, for example, explore the individual
reasons for readmissions, use of other healthcare ser-
vices, etc, is required to substantiate a causal link.
The service aimed to improve the transition of the
patient between care settings which would be best tested
via a randomised control trial. However, prior to carry-
ing this out a feasibility study is required. This work
would determine how best to design the future trial and
identify primary and secondary outcomes that would be
feasible to collect and allow assessment of effectiveness.
The strengths of this study are that it specifically
describes the implementation and operation of an elec-
tronic referral process from hospital to community phar-
macy. We have highlighted possible areas for further
improvement, but feel that the lessons learnt so far are
relevant and valuable to those considering the imple-
mentation of a similar process. The marrying of service
activity with the developmental changes also provides
context to the critical reader in understanding context
and to the service planner of the continual monitoring
and malleability of the service.
A weakness of this evaluation is that there is no test for
fidelity of service delivery and implementation. An inves-
tigation of how well hospital and community pharmacy
staff adhere to the recommended process might provide
further insights into the relatively low referral and com-
pletion rates that have been recorded on PharmOutcomes.
The systematic review by Hesselink et al7 found that
interventions that exhibited specific components, for
example, medicines reconciliation, showed statistically
significant effects in favour of the intervention, that is,
reconciliation reducing the percentage of unreconciled
medication after discharge.7 A future clinical study
should ensure service data collection is appropriate to
allow assessment of intervention effect. The detailed
intervention description provided here will allow better
understanding of facilitators and barriers to outcomes
that will be recorded. This study also highlights a defi-
ciency of the intervention itself: the lack of comprehen-
sive discharge information routinely accompanying the
referral. Another recent systematic review concluded
that those interventions that aimed to identify and
rectify drug-related problems showed the most statistic-
ally significant benefit.8 However to facilitate this, there
needs to be sufficient medication-related information
transferred between healthcare settings. With the recent
announcement that summary care records, an electronic
patient record derived from patients’ GP records will be
provided more widely to community pharmacists,25 it is
anticipated that the information gradient between
primary and secondary care will be reduced.
CONCLUSIONS
Patients in hospitals can be electronically referred to
their nominated community pharmacy upon discharge
from hospital in order to receive a follow-up consult-
ation tailored to their specific need. We have shown that
multiple stakeholders from the hospital, community
pharmacy organisations and IT system developers
working collaboratively could design and implement an
electronic eReferral service from hospital to community
pharmacy. Electronic referral non-completion rates
during the study period appear to be high. This may be
due to this period encompassing the launching and
embedding of such a pioneering service. Early indica-
tions are such that the patients referred from hospital,
who receive a follow-up consultation from their commu-
nity pharmacist, may have lower rates of readmission
and shorter hospital stays.
A feasibility study will identify how and which out-
comes will allow effectiveness of this intervention to be
measured.
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